Cullinan Therapeutics (CGEM) Expected to Announce Quarterly Earnings on Wednesday

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) is expected to be releasing its Q1 2025 earnings data before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($0.80) per share for the quarter.

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.74) EPS for the quarter, beating analysts' consensus estimates of ($0.78) by $0.04. On average, analysts expect Cullinan Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Cullinan Therapeutics Stock Up 2.8%

NASDAQ:CGEM traded up $0.21 during trading hours on Monday, hitting $7.71. 295,580 shares of the company traded hands, compared to its average volume of 584,056. The company has a market cap of $455.01 million, a PE ratio of -2.71 and a beta of -0.07. The firm's 50-day simple moving average is $7.98 and its 200-day simple moving average is $10.23. Cullinan Therapeutics has a one year low of $6.85 and a one year high of $24.99.

Analyst Ratings Changes

CGEM has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $33.00 price objective on shares of Cullinan Therapeutics in a research report on Wednesday, April 16th. Morgan Stanley reissued an "overweight" rating and issued a $35.00 price target (down previously from $38.00) on shares of Cullinan Therapeutics in a research report on Friday, March 7th. Finally, UBS Group reduced their price target on Cullinan Therapeutics from $30.00 to $24.00 and set a "buy" rating for the company in a research report on Monday, May 12th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $32.00.

Insider Buying and Selling

In related news, insider Jeffrey Alan Jones sold 4,895 shares of the business's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $8.53, for a total transaction of $41,754.35. Following the completion of the transaction, the insider now directly owns 174,164 shares in the company, valued at $1,485,618.92. The trade was a 2.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Nadim Ahmed sold 12,529 shares of the company's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $8.53, for a total value of $106,872.37. Following the completion of the transaction, the chief executive officer now owns 430,621 shares in the company, valued at $3,673,197.13. This represents a 2.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.16% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cullinan Therapeutics stock. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 21,581 shares of the company's stock, valued at approximately $163,000. Institutional investors and hedge funds own 86.31% of the company's stock.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.